Technical Analysis for ABBV - AbbVie Inc.

Grade Last Price % Change Price Change
grade B 78.63 1.72% 1.33
ABBV closed up 1.1 percent on Monday, October 21, 2019, on approximately normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Nov 1

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ABBV trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 1.72%
MACD Bullish Signal Line Cross Bullish 1.72%
Expansion Breakout Bullish Swing Setup 1.72%
Pocket Pivot Bullish Swing Setup 1.72%
Stochastic Reached Overbought Strength 1.72%
Upper Bollinger Band Walk Strength 1.72%
Above Upper BB Strength 1.72%
Overbought Stochastic Strength 1.72%
Up 3 Days in a Row Strength 1.72%
Up 4 Days in a Row Strength 1.72%

Older signals for ABBV ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. Its product portfolio includes a range of adult and pediatric pharmaceuticals, including HUMIRA, a biologic therapy administered as a subcutaneous injection to treat various autoimmune diseases; Synthroid used in the treatment of hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has collaboration with Alvine Pharmaceuticals, Inc. to develop a oral treatment for patients with celiac disease. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013.AbbVie Inc. operates independently of Abbott Laboratories.
Chemistry Chemical Compounds Organic Compounds Pharmaceutical Products Autoimmune Diseases Prostate Cancer Chloroarenes Cardiology Cholesterol Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Lipoproteins Secondary Hyperparathyroidism Celiac Disease Exocrine Pancreatic Insufficiency Hypothyroidism Research Based Biopharmaceutical Testosterone Replacement Therapy
Is ABBV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 94.98
52 Week Low 62.66
Average Volume 7,646,378
200-Day Moving Average 75.9021
50-Day Moving Average 70.2322
20-Day Moving Average 74.233
10-Day Moving Average 74.682
Average True Range 1.4651
ADX 28.04
+DI 33.202
-DI 12.435
Chandelier Exit (Long, 3 ATRs ) 73.45469999999999
Chandelier Exit (Short, 3 ATRs ) 75.96529999999999
Upper Bollinger Band 76.7693
Lower Bollinger Band 71.6967
Percent B (%b) 1.1
BandWidth 6.833349
MACD Line 1.4635
MACD Signal Line 1.3634
MACD Histogram 0.1001
Fundamentals Value
Market Cap 123.23 Billion
Num Shares 1.59 Billion
EPS 4.07
Price-to-Earnings (P/E) Ratio 18.99
Price-to-Sales 5.35
Price-to-Book 23.76
PEG Ratio 1.00
Dividend 2.56
Dividend Yield 3.31%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 80.30
Resistance 3 (R3) 80.15 79.00 79.80
Resistance 2 (R2) 79.00 78.24 79.08 79.63
Resistance 1 (R1) 78.15 77.76 78.58 78.30 79.47
Pivot Point 77.00 77.00 77.21 77.08 77.00
Support 1 (S1) 76.15 76.24 76.58 76.30 75.13
Support 2 (S2) 75.00 75.76 75.08 74.97
Support 3 (S3) 74.15 75.00 74.80
Support 4 (S4) 74.30